This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shulman, N. Articles by Sun, E. Search for Related Content PubMed PubMed Citation Articles by Shulman, N. Articles by Sun, E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2002, p. 3907-3916, Vol. 46, No. 12
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.12.3907-3916.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Virtual Inhibitory Quotient Predicts Response to Ritonavir Boosting of Indinavir-Based Therapy in Human Immunodeficiency Virus-Infected Patients with Ongoing Viremia

Stanford University School of Medicine, Stanford, California,¹ University of California, San Diego, San Diego, California,² Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois,³ Johns Hopkins School of Medicine, Baltimore, Maryland,⁴ Southwestern Medical School, University of Texas, Dallas, Texas⁵

Received 21 May 2002/ Returned for modification 8 August 2002/ Accepted 12 September 2002

Depending on the degree of underlying resistance present, optimization of the pharmacokinetics of protease inhibitors may result in improved virologic suppression. Thirty-seven human immunodeficiency virus (HIV)-infected subjects who had chronic detectable viremia and who were receiving 800 mg of indinavir three times a day (TID) were switched to 400 mg of indinavir BID with 400 mg of ritonavir two times a day (BID) for 48 weeks. Full pharmacokinetic evaluations were obtained for 12 subjects before the switch and 3 weeks after the switch. Combination therapy increased the indinavir predose concentrations in plasma by 6.47-fold, increased the minimum concentration in serum by 3.41-fold, and reduced the maximum concentration in serum by 57% without significantly changing the area under the plasma concentration-time curve at 24 h. At week 3, 58% (21 of 36) of the subjects for whom postbaseline measurements were available achieved a viral load in plasma of <50 copies/ml or a reduction from the baseline load of 0.5 log₁₀ copies/ml. Of these subjects, 82% (14 of 17) whose viruses had three or fewer protease inhibitor mutations and 88% (14 of 16) whose viruses had an indinavir virtual phenotypic susceptibility test of more than sixfold less than that for the baseline isolate were considered virologic responders. The indinavir virtual inhibitory quotient, which is a function of baseline indinavir phenotypic resistance (estimated by virtual phenotype) and the indinavir predose concentration in plasma achieved with indinavir-ritonavir combination therapy, was the best predictor of a viral load reduction. Sixteen subjects discontinued the study by week 48 due to adverse events, predominantly related to hyperlipidemia. Pharmacokinetic intensification of indinavir-based therapy with ritonavir reduced the viral loads in subjects but added toxicity. The virtual inhibitory quotient, which incorporates both baseline viral resistance and the level of drug exposure in plasma, was superior to either baseline resistance or drug exposure alone in predicting the virologic response.

This article has been cited by other articles:

• Dicenzo, R., Luque, A., Larppanichpoonphol, P., Reichman, R. (2006). Association of total bilirubin with indinavir and lopinavir plasma concentrations in HIV-infected patients receiving three different double-boosted dosing regimens. J Antimicrob Chemother 58: 393-400 [Abstract] [Full Text]  
• Marcelin, A.-G., Cohen-Codar, I., King, M. S., Colson, P., Guillevic, E., Descamps, D., Lamotte, C., Schneider, V., Ritter, J., Segondy, M., Peigue-Lafeuille, H., Morand-Joubert, L., Schmuck, A., Ruffault, A., Palmer, P., Chaix, M.-L., Mackiewicz, V., Brodard, V., Izopet, J., Cottalorda, J., Kohli, E., Chauvin, J.-P., Kempf, D. J., Peytavin, G., Calvez, V. (2005). Virological and Pharmacological Parameters Predicting the Response to Lopinavir-Ritonavir in Heavily Protease Inhibitor-Experienced Patients. Antimicrob. Agents Chemother. 49: 1720-1726 [Abstract] [Full Text]  
• Csajka, C., Marzolini, C., Fattinger, K., Decosterd, L. A., Telenti, A., Biollaz, J., Buclin, T. (2004). Population Pharmacokinetics of Indinavir in Patients Infected with Human Immunodeficiency Virus. Antimicrob. Agents Chemother. 48: 3226-3232 [Abstract] [Full Text]  
• Hickman, D., Vasavanonda, S., Nequist, G., Colletti, L., Kati, W. M., Bertz, R., Hsu, A., Kempf, D. J. (2004). Estimation of Serum-Free 50-Percent Inhibitory Concentrations for Human Immunodeficiency Virus Protease Inhibitors Lopinavir and Ritonavir. Antimicrob. Agents Chemother. 48: 2911-2917 [Abstract] [Full Text]  
• Piliero, P. J. (2003). Early Factors in Successful Anti-HIV Treatment. J Int Assoc Physicians AIDS Care (Chic Ill) 2: 10-20 [Abstract]